Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non–small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. METHODS: Patients with s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Oncol Pract
Autores principales: Carroll, Nikki M., Delate, Thomas, Menter, Alex, Hornbrook, Mark C., Kushi, Lawrence, Aiello Bowles, Erin J., Loggers, Elizabeth T., Ritzwoller, Debra P.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2015
Materias:
Health Care Delivery
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4575400/
https://ncbi.nlm.nih.gov/pubmed/26060223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.2014.002980
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares